Two heavyweight new drugs will be launched in Xiansheng pharmaceutical next year

On December 1, at the annual customer appreciation meeting, Xiansheng pharmaceutical released new drugs to be launched next year, including enritane (bendamostine) for chronic / small lymphocytic leukemia and prochang (pramipexole) for Parkinson's disease, among which enritane was the first drug in China 20 years of Xiansheng pharmaceutical: change and innovation As Ren Jinsheng, chairman of Xiansheng pharmaceutical, said in the company's commemorative video, in the past 20 years, Xiansheng has chosen a unique and rugged road To sum up the key words of 20 years for the first time, "change" and "innovation" are the key words In 1995, Jiangsu Chenggong Pharmaceutical Co., Ltd was established, which was the first "general agent" mode in the enterprise But only a year later, the company began to encounter many setbacks, such as the dissolution of the entrepreneurial team, the request of partners to terminate the general distribution right, etc in 1999, the company changed its name to Xiansheng pharmaceutical Through years of independent R & D and capital operation, the company has established development strategies in five treatment fields, including anti-tumor, cardio cerebrovascular, central nervous system, anti infection, anti-inflammatory and analgesic In 2007, it became the first chemical and biological drug company listed on NYSE Since this year, Xiansheng has begun to turn its attention to the field of large-scale health and mobile medical care, which is in the wind, and has made some explorations Next, we will make efforts in traditional medicine, open research and development, Internet medicine, and big health at the same time In two decades, Xiansheng pharmaceutical has grown from 2.78 million registered capital to more than 3 billion assets, and its employees have grown from dozens to more than 3000 It has successively established four well-known domestic trademarks, namely "Xiansheng", "Relin", "Yingtaiqing" and "Bicun" For the achievements of these years, Ren Jinsheng believes that billions of sales, billions of total assets and thousands of employees are only digital manifestations, and the biggest change is the maturity and growth of self First, after the 20th anniversary, we should be more open, introspective and start again In terms of R & D, the pioneer pharmaceutical industry gained products such as endu, zhongrenfu'an and jebshu by M & A in its initial stage, so as to realize rapid growth Meanwhile, it also attached importance to its own innovation power and made a "focus" on R & D It is understood that in the last six years alone, the annual R & D investment of Xiansheng pharmaceutical industry accounts for about 10% of the sales share, and the cumulative R & D investment is nearly 1.2 billion yuan, which is still increasing year by year In 2000, Xiansheng new drug research center was established, which is the first in China to develop and survive Three years later, Xiansheng group and Xiansheng Pharmaceutical Research Institute were formally established In 2004, edaravone injection, a new drug for stroke treatment, was successfully developed independently, becoming the first product in China and the second product in the world on the market, thus successfully entering the field of nervous system treatment According to reports, the drug is used by millions of patients every year, bringing 800 million annual sales to Xiansheng Different from the habit of "building a car behind closed doors" of domestic enterprises, the pioneer pharmaceutical industry has chosen to open the door and welcome colleagues to explore new drug research and development together Last year, Xiansheng established baijiahui entrepreneurial community to open its R & D and pharmaceutical platform resources to scientists and entrepreneurs around the world, thus creating a domestic open drug R & D model At present, more than 60 companies have settled in the park, covering various fields such as biological immunity, chemical pharmacy, medical equipment, cro platform, etc., and initially forming the scale of life science entrepreneurial community cluster In the next five years, baijiahui will introduce 5-6 investment companies every year, and the number of companies settled will increase by more than 20-30 every year It is expected that by 2019, there will be more than 300 settled start-ups, and several of them will be listed It is understood that recently, the Ministry of science and technology of the people's Republic of China has approved the construction of the National Key Laboratory of the enterprise "transformation medicine and innovative medicine" in the pioneer pharmaceutical industry In addition, on December 1, Xiansheng was also named "2015 China's innovative pharmaceutical enterprise" by the China Pharmaceutical Information Center of the Ministry of industry and information technology Feng Honggang said that, next, Xiansheng will continue to increase investment in research and development, maintain the leading level of research and development of exclusive new drugs and first generic drugs, comprehensively promote GMP certification in Europe and the United States, and thoroughly solve the problem of consistency evaluation At the same time, relying on the construction of the above-mentioned national key laboratories, we will create R & D advantages in the field of precision medicine.